Medical NewsCDSCO Panel Backs Label Change Allowing Endocrinologists, Rheumatologists to Prescribe Amgen’s Romosozumab DRRA1 day ago01 mins [ad_1] CDSCO Panel Backs Label Change Allowing Endocrinologists, Rheumatologists to Prescribe Amgen’s Romosozumab We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link Post navigation Previous: Stellate Ganglion Block Reduces Postoperative Pain and Opioid Use After Laparoscopic Hysterectomy: StudyNext: JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment.
FDA again rejects tabelecleucel for EBV-driven post-transplant lymphoproliferative disease DRRA1 day ago 0